Lymphocyte - Monocyte Ratio As An Independent Predictor For Progression Of Illness In Patients With Covid-19

Completed

• Conditions: Covid19
• Interventions: Diagnostic Test: LYMPHOCYTE MONOCYTE RATIO

• Registration Number: NCT04534712
• Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Brief Summary

Corona virus disease 2019 (COVID 19), first identified in December 2019 in a cluster of population in a Chinese province, soon emerged as a pandemic, causing a huge strain on healthcare system and mortality all over the world. An ideal marker for predicting course of this illness should be easily available and reproducible; as the disease burden has spread to third world countries whose healthcare system is resource limited. Our study is aimed to study the utility of lymphocyte- monocyte ratio in the early stages to predict the progression of COVID 19 pneumonia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-08-30
• Study First Submitted QC: 2020-08-30
• Study Start: 2020-09-01
• Study First Posted: 2020-09-01
• Primary Completion: 2021-10-01
• Study Completion: 2021-10-01
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-30
• Last Update Posted: 2023-04-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• All adults of age 18-80 years tested positive for SARS-CoV-2 reverse-transcriptase - polymerase chain reaction (rt-PCR) and presented within 7 days of symptom(s) onset

Exclusion Criteria

• Pregnancy
• Sepsis
• Malignancy
• Patients on immunosuppressant therapy
• Chronic inflammatory conditions
• Cases lost to follow up

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
PROGRESSION	LYMPHOCYTE MONOCYTE RATIO	Cohort A with patients who progressed to next stage of illness or continue to remain in the same stage
NON PROGRESSION	LYMPHOCYTE MONOCYTE RATIO	Cohort B with those who improved by two points on the ordinal scale without any further progression

Primary Outcome Measures

Name	Time	Method
progression	28 days	disease progression equal or more than 2 stages

Secondary Outcome Measures

Name	Time	Method
mortality	28 days	end outcome of the patients diagnosed of COVID-19 infection

Trial Locations

Locations (1)

Sir Ganga Ram Hospital; 🇮🇳 New delhi, Delhi, India